Literature DB >> 19547812

Vestibular rehabilitation: clinical benefits to patients with Parkinson's disease.

Bianca Simone Zeigelboim1, Karlin Fabianne Klagenberg, Hélio A Ghizoni Teive, Renato Puppi Munhoz, Jackeline Martins-Bassetto.   

Abstract

OBJECTIVE: To evaluate the effectiveness of the vestibular rehabilitation (VR) exercises by means of an assessment before and after the application of the Brazilian version of the Dizziness Handicap Inventory (DHI) questionnaire.
METHOD: Twelve patients were studied, the following procedures were carried out: anamnesis, otorhinolaryngological and vestibular evaluation, and the application of the DHI before and after the VR.
RESULTS: Clinically resting tremors and subjective postural instability were the motor complaints most frequently associated with complaints of vertigo in 12 cases (100%); in the vestibular exam, all the patients presented abnormalities, frequently from the uni and bilateral peripheral vestibular deficiency syndromes in 10 cases (83.3%); there was significant improvement in the physical, functional and emotional aspects of the DHI after the completion of the VR.
CONCLUSION: The VR following the Cawthorne and Cooksey protocol were shown to be useful in managing subjective complaints of several aspects evaluated in this protocol.

Entities:  

Mesh:

Year:  2009        PMID: 19547812     DOI: 10.1590/s0004-282x2009000200009

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  2 in total

1.  Does visuospatial motion perception correlate with coexisting movement disorders in Parkinson's disease?

Authors:  Sinem Balta Beylergil; Palak Gupta; Mohamed ElKasaby; Camilla Kilbane; Aasef G Shaikh
Journal:  J Neurol       Date:  2021-09-23       Impact factor: 4.849

Review 2.  Vestibular Deficits in Neurodegenerative Disorders: Balance, Dizziness, and Spatial Disorientation.

Authors:  Thomas Cronin; Qadeer Arshad; Barry M Seemungal
Journal:  Front Neurol       Date:  2017-10-26       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.